Maria Queralt Salas

List of Publications by Year
in descending order

32 papers	337 citations	1039880 9 h-index	887953 17 g-index
33 all docs	33 docs citations	33 times ranked	443 citing authors

#	Article	IF	Citations
1	Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: A single-center experience. Hematology, Transfusion and Cell Therapy, 2022, 44, 440-443.	0.1	4
2	Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Study. Transplantation and Cellular Therapy, 2022, 28, 50.e1-50.e8.	0.6	11
3	Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. Transplantation and Cellular Therapy, 2022, 28, 265.e1-265.e9.	0.6	6
4	PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. Transplantation and Cellular Therapy, 2022, 28, 489.e1-489.e9.	0.6	7
5	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience. Cancers, 2022, 14, 2673.	1.7	4
6	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 60-69.	1.3	26
7	Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. Bone Marrow Transplantation, 2021, 56, 689-691.	1.3	1
8	Prolactin, a potential biomarker for chronic GVHD activity. European Journal of Haematology, 2021, 106, 158-164.	1.1	2
9	Use of Telehealth for Domiciliary Follow-up After Hematopoietic Cell Transplantation During the COVID-19 Pandemic: Prospective Pilot Study. JMIR Formative Research, 2021, 5, e26121.	0.7	8
10	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 428.e1-428.e9.	0.6	11
11	Effect of preâ€transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. European Journal of Haematology, 2021, 107, 517-528.	1.1	2
12	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. Leukemia and Lymphoma, 2021, 62, 3373-3383.	0.6	12
13	Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation. Blood Advances, 2021, 5, 3418-3426.	2.5	17
14	Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era. Blood, 2021, 138, 3925-3925.	0.6	0
15	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). Blood, 2021, 138, 3880-3880.	0.6	4
16	Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. European Journal of Haematology, 2020, 104, 145-147.	1.1	24
17	Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution. Leukemia and Lymphoma, 2020, 61, 575-581.	0.6	3
18	Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. European Journal of Haematology, 2020, 104, 36-45.	1.1	7

#	Article	IF	Citations
19	Graft-versus-Host Diseaseâ€“Free Relapse-Free Survival Definition for Patients with Nonmalignant Hematologic Disorders. Biology of Blood and Marrow Transplantation, 2020, 26, 428.	2.0	2
20	Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. Biomarkers, 2020, 25, 69-75.	0.9	14
21	Allogeneic Hematopoietic Transplantation for Multiple Myeloma in the New Drugs Era: A Platform to Cure. Journal of Clinical Medicine, 2020, 9, 3437.	1.0	3
22	High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. Leukemia and Lymphoma, 2020, 61, 3198-3208.	0.6	9
23	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1511-1519.	2.0	6
24	Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. Bone Marrow Transplantation, 2020, 55, 1773-1783.	1.3	35
25	Impressive Graft-versus-Host Disease-Free, Relapse-Free Survival in Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning and a Combination of Antithymocyte Globulin and Post-Transplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2019, 25, e352-e353.	2.0	3
26	Dual T Cell Depletion with Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide Results in Low Rates of Cytokine Release Syndrome in Peripheral Blood Haplo-Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e387-e388.	2.0	4
27	Reducedâ€intensity conditioning allogeneic transplant with dual Tâ€cell depletion in myelofibrosis. European Journal of Haematology, 2019, 103, 597-606.	1.1	9
28	Reduced intensity allogeneic stem cell transplant with antiâ€thymocyte globulin and postâ€transplant cyclophosphamide in acute myeloid leukemia. European Journal of Haematology, 2019, 103, 510-518.	1.1	19
29	Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis. Clinical Hematology International, 2019, 1, 105-113.	0.7	18
30	Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. Blood, 2019, 134, 3344-3344.	0.6	0
31	Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. Blood, 2019, 134, 4590-4590.	0.6	0
32	Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2018, 24, 2259-2264.	2.0	66